Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia

Published: Monday, May 13, 2013
Last Updated: Monday, May 13, 2013
Bookmark and Share
Detailed design, generation and testing of the Ylanthia library.

MorphoSys AG has announced that a first scientific publication on the Company's novel, proprietary antibody platform Ylanthia was published in the current issue of "mAbs".

The article titled "A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties" describes for the first time the detailed design, generation and testing of the Ylanthia library.

Ylanthia became commercially available for existing and new partners in 2012 and is currently used in two commercial agreements.

"Ylanthia sets new standards for therapeutic antibody generation. Its unique and innovative design translates into unprecedented structural diversity which is expected to result in antibodies against previously inaccessible target molecules and covering a unique epitope space. Furthermore, our scientists introduced an entirely new concept to improve biophysical characteristics that are relevant for antibody selection, manufacturing and administration, finally leading to better drugs," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

To confirm the functionality and quality of the Ylanthia antibody library, phage selections against several antigens were performed.

Subsequent antibody characterization revealed broad diversity and significantly improved biophysical properties including a very low aggregation tendency, increased thermodynamic stability and favorable solubility of Ylanthia antibodies.

Ylanthia comprises more than 100 billion distinct, fully human antibodies, which makes it the industry's largest known antibody Fab library. It uses 36 fixed, naturally-occurring heavy and light chain framework combinations, which translates into very broad structural diversity.

Ylanthia's antibody frameworks were pre-selected for favorable expression levels, stability and aggregation behavior.

A shift towards higher stability and stress tolerance will increase shelf life and serum stability of resulting antibody products, making them more cost-effective to produce.

A higher solubility in turn opens up the path for more convenient ways of administration, to the benefit of patients.

When needed, antibodies from the Ylanthia library are optimized using MorphoSys's proprietary Slonomics technology.

Slonomics enables optimization of Ylanthia antibodies with unprecedented speed and flexibility.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys, MD Anderson Partner
MorphoSys AG and The University of Texas MD Anderson Cancer Center have announced a long-term strategic alliance for the discovery and development of novel therapeutic antibodies against cancer.
Wednesday, May 25, 2016
MorphoSys Announces Clinical Milestone for Start of Bayer's Phase 2 Trial
Phase 2 trial designed to support registration of anetumab ravtansine.
Wednesday, January 27, 2016
MorphoSys Publishes Update on MOR202 in Multiple Myeloma
First data from final 16 mg/kg dose escalation cohort and combination with immunomodulatory drugs show encouraging activity.
Thursday, September 24, 2015
MorphoSys to Receive Milestone Payment for Guselkumab Program
Company initiates phase 2 clinical trial in psoriatic arthritis with the HuCAL antibody.
Tuesday, April 14, 2015
MorphoSys Nominates Three New Candidates for Supervisory Board
Company has nominated Ms. Wendy Johnson, Mr. Klaus Kühn and Dr. Frank Morich.
Tuesday, March 31, 2015
MorphoSys and Celgene Mutually Agree to End MOR202 Collaboration
MorphoSys regains rights to MOR202 antibody against CD38 and updates its financial guidance for 2015.
Friday, March 27, 2015
MorphoSys Provides Update on the Company's Proprietary Drug Portfolio
Early-stage portfolio now fully Ylanthia-based, includes programs with Merck Serono as well as first anti-GPCR programs.
Tuesday, July 29, 2014
MorphoSys Strengthens Clinical Development Organization with Three Management Appointments
Appointment of Dr. Gabriele Elbl, Dr. Ludger Langer and Dr. Steffen Heeger.
Monday, December 23, 2013
MorphoSys Announces Additional Clinical Trial of MOR208
Phase 2 study in CLL will evaluate MOR208 in combination with lenalidomide.
Wednesday, December 11, 2013
MorphoSys Strengthens European Patent Position on Anti-CD19 Cancer Program MOR208
New patent has a scheduled expiry date in 2027.
Tuesday, December 03, 2013
MorphoSys Strengthens Patent Position on anti-CD19 Cancer Program MOR208
New patent covers the antibody's protein sequence.
Tuesday, October 22, 2013
MorphoSys and Xencor Provide Update on Phase 1/2a Trial in CLL/SLL for MOR208
Extended treatment resulted in higher overall response rate.
Tuesday, October 08, 2013
MorphoSys Collaborator to Start Pivotal Study with Bimagrumab
MorphoSys to receive clinical milestone payment.
Thursday, October 03, 2013
MorphoSys Receives Two Phase 2 Milestone Payments from Janssen
MOR202 in phase 1/2a trial for multiple myeloma.
Tuesday, September 17, 2013
MorphoSys Closes on the Alliance with Celgene for MOR202 and Increases Financial Guidance
Celgene acquires 3.4 % equity stake via a capital increase.
Monday, August 12, 2013
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Itchy Inflammation Of Mosquito Bites Helps Viruses Replicate
The itchy swelling that appears at the site of a mosquito bite isn't just an irritating nuisance - it also makes viral infections spread by the insects far worse, new research has found.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Revealing T-Cells in Action
Salk scientists show how T-cell receptors reposition during an immune response, revealing more on how the immune system is regulated.
Impact of Antibiotic Treatment on the Infant Gut Microbiome
Study shows that antibiotic treatment reduces stability and diversity of microbial population in the first three years of life.
Viruses Hack Their Host's Genome with CRISPR
A virus that infects major freshwater bacteria appears to use stolen bits of immune system DNA to highjack their hosts’ immune response.
Reclaiming The Immune System's Assault On Tumors
EPFL study shows a way to reclaim corrupted immune cells.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!